📈 Jumpstart Signal Watchlist — August 25, 2026

🏢 What they do: The Manitowoc Company is a global manufacturer of engineered lifting solutions, mainly cranes and related equipment. Its products include mobile hydraulic cranes, tower cranes, crawler cranes, boom trucks, and associated aftermarket services and support.
- 🎯 Current $19.48 is 7% below 3yr high $20.87 · ⏳ SMA200 $13.27 (current price $19.48 is above) · 💰 Market Cap $702M
- MTW shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 875% (>20%); Low LT D/E 0.66 (<1.0); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (8.6%)
- 🔔 Strong above EMA50 (22.5%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Manitowoc (NYSE:MTW) Hits New 52-Week High — MarketBeat.
🤖 The stock reached a new 52-week high after the company’s strong quarterly results and raised 2026 outlook. Higher earnings, stronger orders, and improved guidance are supportive for MTW.
✅ Manitowoc (NYSE:MTW) Announces Earnings Results — MarketBeat.
🤖 Manitowoc beat expectations with $0.46 EPS versus $0.11 consensus and revenue of $594.9 million, and it raised FY 2026 guidance. The strong earnings surprise and forward outlook are positive for the shares.
⚪️ The Manitowoc Company to Present and Host 1x1 Meetings at the Midwest IDEAS Investor Conference — Business Wire.
🤖 This is a routine investor-relations announcement about a conference presentation and 1x1 meetings, with no new operating results or guidance. It is not likely to move MTW much on its own.
⚪️ Wells Fargo & Company Issues Positive Forecast for Manitowoc (NYSE:MTW) Stock Price — MarketBeat.
🤖 Wells Fargo raised its price target to $12 while keeping an underweight rating, which is mixed for the stock. The note is mildly supportive on valuation but still signals caution.
🍭 Bonus (B): 0/10 — Construction Machinery

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $56.72 is 1% below 3yr high $57.10 · ⏳ SMA200 $46.85 (current price $56.72 is above) · 💰 Market Cap $14.1B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (5.2%)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 3/10
- 🗞️ News sentiment is negative (mixed coverage).
✅ BlackRock Inc. Purchases New Stake in Exelixis, Inc. $EXEL — MarketBeat.
🤖 The filing says BlackRock built a very large new position in Exelixis, which can be supportive for investor confidence. However, the piece also notes insider selling and a still-muted consensus view, so the impact is only modestly positive.
❌ Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot — Yahoo Finance.
🤖 The article says Exelixis lowered its 2026 revenue outlook to $2.50 billion-$2.55 billion after reporting Q2 results, and the stock fell on the news. Although EPS beat expectations, the guidance cut and slower NET growth are negative for the shares.
❌ Exelixis Q2 2026 slides: strong earnings, but NET slowdown cuts guidance — Investing.com.
🤖 Exelixis beat EPS estimates, but revenue came in slightly below consensus and the company reduced full-year 2026 revenue guidance by about $50 million at the midpoint. The market reaction was negative, with shares falling after hours.
⚪️ BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" — MarketBeat.
🤖 BMO’s upgrade to hold matches the broader consensus rather than signaling a more bullish view. The note acknowledges strong EPS but also the reduced 2026 revenue guidance, making the overall read mixed.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: American Healthcare REIT, Inc. (NYSE: AHR) is a real estate investment trust that acquires, owns, and operates a diversified portfolio of clinical healthcare properties, focusing primarily on senior housing communities, skilled nursing facilities, and outpatient medical buildings across the United States, the United Kingdom, and the Isle of Man.
- 🎯 Current $57.05 is 1% below 3yr high $57.72 · ⏳ SMA200 $50.36 (current price $57.05 is above) · 💰 Market Cap $11.1B
- AHR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (14.1% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 167% (>20%); Revenue growth 27% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 5/20
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ American Healthcare REIT Announces Second Quarter 2026 Results, Increases Full-Year 2026 Guidance — Business Wire.
🤖 The company reported strong same-store NOI growth and raised full-year 2026 guidance for NFFO per share, which is supportive for the stock. The results showed solid operating momentum despite mixed GAAP earnings.
✅ American Healthcare REIT (NYSE:AHR) Releases Earnings Results, Beats Estimates By $0.40 EPS — MarketBeat.
🤖 American Healthcare REIT beat EPS expectations and increased its 2026 guidance, both of which are typically bullish signals. Revenue missed the consensus forecast, but the earnings surprise and guidance lift make the release net positive.
✅ American Healthcare REIT, Inc. (NYSE:AHR) Receives Average Recommendation of "Moderate Buy" from Analysts — MarketBeat.
🤖 Analysts remained broadly constructive, with a Moderate Buy consensus and an above-market average price target. Continued favorable coverage can support sentiment around the stock.
🍭 Bonus (B): 0/10 — REITs

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.78 is 2% below 3yr high $35.53 · ⏳ SMA200 $24.52 (current price $34.78 is above) · 💰 Market Cap $4.4B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026 and Raises FY 2026 Guidance — Business Wire.
🤖 Concentra reported strong Q2 results, with revenue up 10.0% year over year, net income up 46.5%, and Adjusted EBITDA up 22.5%. The company also raised full-year 2026 guidance and announced leadership changes, which are generally supportive for the stock.
✅ Truist Financial Raises Concentra Group Holdings Parent Price Target to $42.00 — MarketBeat.
🤖 This is positive because it reflects a higher analyst valuation after Concentra’s earnings beat and revenue outperformance. A higher price target from a major broker can improve sentiment and support the share price.
✅ Concentra Group Holdings Parent (NYSE:CON) Sets New 1-Year High — MarketBeat.
🤖 The article highlights that Concentra beat quarterly expectations and reached a new 52-week high, both of which are favorable signals for momentum. It also notes continued broadly positive analyst sentiment.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 Current $56.19 is 5% below 3yr high $58.89 · ⏳ SMA200 $43.43 (current price $56.19 is above) · 💰 Market Cap $1.1B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%); Low LT D/E 0.38 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ ScanSource to Acquire MicroAge, a Leading IT Solutions Integrator — Business Wire.
🤖 ScanSource announced a definitive all-cash agreement to acquire MicroAge for $220.5 million, a move that expands its cloud, cybersecurity, and managed-services capabilities. The acquisition could strengthen growth prospects if integration goes well.
✅ ScanSource Delivers Strong Fourth Quarter and Full-Year Results — Business Wire.
🤖 ScanSource reported fiscal Q4 revenue of $953.1 million, up 17.3% year over year, and highlighted strong full-year results. The earnings release also supports a favorable outlook by showing solid operating momentum.
✅ ScanSource shares jump 19% after Q4 beat and $220.5 million MicroAge deal — Yahoo Finance.
🤖 The stock rose sharply after ScanSource beat expectations and announced the MicroAge acquisition. Investors appeared to reward both the earnings upside and the strategic expansion plan.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale

🏢 What they do: Laureate Education, Inc. (LAUR) owns and operates a network of higher education institutions in Mexico, Peru, and the United States, offering undergraduate and graduate degree programs in business, medicine, health sciences, engineering, and information technology through campus-based, online, and hybrid formats.
- 🎯 Current $38.36 is 5% below 3yr high $40.46 · ⏳ SMA200 $34.23 (current price $38.36 is above) · 💰 Market Cap $5.3B
- LAUR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 51% (>20%); Revenue growth 17% (>15%); ROE 28% (>15%); Low LT D/E 0.14 (<1.0).
⏰ Entry (E): 4/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Neumeier Poma Investment Counsel LLC Acquires New Shares in Laureate Education $LAUR — MarketBeat.
🤖 This institutional buying suggests continued investor interest in LAUR. The article also notes the company’s recent earnings beat and raised fiscal 2026 outlook, which supports a constructive view on the stock.
✅ Bank of America Corp DE Has $13.86 Million Holdings in Laureate Education $LAUR — MarketBeat.
🤖 The article highlights a larger institutional position in LAUR, which is generally supportive for sentiment. It also references Laureate’s earnings beat and full-year guidance, reinforcing the stock’s positive fundamentals.
❌ JPMorgan Chase & Co. Reiterates Neutral Rating for Laureate Education (NASDAQ:LAUR) — MarketBeat.
🤖 A neutral rating from a major bank and a modest price target can weigh on sentiment. The downgrade followed the stock’s strong run, suggesting valuation concerns may limit upside.
⚪️ Laureate Education (NASDAQ:LAUR) Receives Consensus Recommendation of "Hold" from Brokerages — MarketBeat.
🤖 The article is mixed rather than strongly bullish or bearish, with a consensus Hold rating and a price target above the recent share price. It points to solid quarterly results but does not signal a major near-term catalyst.
🍭 Bonus (B): 0/10 — Educational Services